| |
LGE negative n = 21
|
LGE positive n = 16
|
p
|
|---|
|
Cardiovascular risk factors
|
|
Diabetes
|
3 (14%)
|
4 (25%)
|
0.41
|
|
Hypertension
|
8 (38%)
|
5 (31%)
|
0.67
|
|
Smokinga
|
8 (38%)
|
5 (31%)
|
0.98
|
|
Hyperlipidemia
|
2 (10%)
|
4 (25%)
|
0.21
|
|
Family history of CVD
|
6 (29%)
|
5 (31%)
|
0.86
|
|
Obesity (BMI ≥ 30 kg/m2)
|
6 (29%)
|
3 (19%)
|
0.49
|
|
Symptoms (multiple possible)
|
|
Angina
|
2 (10%)
|
4 (25%)
|
0.21
|
|
Dyspnea
|
8 (38%)
|
8 (50%)
|
0.55
|
|
Palpitations
|
2 (10%)
|
2 (13%)
|
0.72
|
|
Syncope
|
-
|
1 (6%)
|
0.25
|
|
ECG abnormality
|
5 (24%)
|
6 (38%)
|
0.37
|
|
Years since diagnosis
|
|
< 1
|
8 (38%)
|
4 (25%)
|
0.57
|
|
1–4
|
5 (24%)
|
6 (38%)
|
0.63
|
|
5–9
|
7 (33%)
|
4 (25%)
|
0.67
|
|
≥ 10
|
1 (5%)
|
2 (13%)
|
0.39
|
|
Disease Activity
|
|
BVAS
|
4 (1–19)
|
6 (2.5–12.5)
|
0.91
|
|
Hematocrit
|
0.39 (0.32–0.41)
|
0.41 (0.38–0.44)
|
0.10
|
|
Medication
|
|
Beta-blockers
|
5 (24%)
|
4 (25%)
|
0.93
|
|
ARB
|
10 (48%)
|
4 (25%)
|
0.16
|
|
ASA
|
-
|
5 (31%)
| |
|
CCB
|
6 (29%)
|
2 (13%)
|
0.24
|
|
Statins
|
1 (5%)
|
2 (13%)
|
0.37
|
|
Diuretics
|
4 (19%)
|
4 (25%)
|
0.66
|
|
Steroids
|
21 (100%)
|
16 (100%)
|
0.16
|
|
NSAID
|
1 (5%)
|
-
| |
|
Antibodies
|
2 (10%)
|
-
| |
|
Cyclophosphamide
|
11 (52%)
|
6 (38%)
|
0.67
|
|
Azathioprine
|
1 (5%)
|
3 (19%)
|
0.18
|
|
Methotrexate
|
2 (10%)
|
3 (19%)
|
0.42
|
- All values are n (%) or interquartile ranges. CVD cardiovascular disease, BMI body mass index, ECG electrocardiogram, BVAS Birmingham vasculitis activity score, ARB angiotensin receptor blockers, ASA acetylsalicylic acid, CCB calcium channel blockers, NSAID nonsteroidal anti-inflammatory drug
-
aCurrent or ever-smokers
